Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 50 of 2407

TitleReference numberPublishedLast updated
Non-indicator text resourceCG1027
Test Syndication - IFPNG295
MLB test IFP resource for syndicationNG296
HTE temp withdrawnHST120
Temp Withdrawn TestCG203
Master test-639NG243
Claire testCG8923
PUB602 pretestNG242
Master new feeds testCG273
NG Pdf testNG275
Test Product 554DG65
Test Product 554CG272
DG test -636DG92
Test PUB636CG200
PUB550 testCG279
PUB550 testCG197
DG Content Order testDG95
Content Order testCG199
Master test-552DG91
PUB-552 testDG90
Master Pub testCG195
Conversion word testCG194
PUB-545 Resource Type testDG59
Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgusIPG789
Tafamidis for treating transthyretin amyloidosis with cardiomyopathyTA984
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinomaTA983
Voxelotor for treating haemolytic anaemia caused by sickle cell diseaseTA981
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)TA980
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutationTA979
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)TA978
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and overTA977
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndromeHST31
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Ranibizumab for treating choroidal neovascularisation associated with pathological myopiaTA298
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283
Ranibizumab and pegaptanib for the treatment of age-related macular degenerationTA155
Image-guided percutaneous laser ablation for primary and secondary liver tumoursIPG788
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetesIPG787
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liverIPG786
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underTA975
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Atogepant for preventing migraineTA973
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancerDG58
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatmentsTA970

Results per page

  1. 10
  2. 25
  3. 50
  4. All